RSNA 2016

Abstract Archives of the RSNA, 2016


SSG03-01

Transitional Changes in Interstitial Lung Disease Using HRCT to Assess the Impact of Treatment with Cyclophosphamide or Mycophenolate: Results of Scleroderma Lung Study II

Tuesday, Nov. 29 10:30AM - 10:40AM Room: S404CD



Hyung J. Kim, PhD, Los Angeles, CA (Presenter) Nothing to Disclose
Pechin Lo, Los Angeles, CA (Abstract Co-Author) Nothing to Disclose
Donald P. Tashkin, MD, Los Angeles, CA (Abstract Co-Author) Nothing to Disclose
Matthew S. Brown, PhD, Los Angeles, CA (Abstract Co-Author) Nothing to Disclose
David W. Gjertson, PhD, Los Angeles, CA (Abstract Co-Author) Nothing to Disclose
Peiyun Lu, Los Angeles, CA (Abstract Co-Author) Nothing to Disclose
Danny Chong, MS, Los Angeles, CA (Abstract Co-Author) Nothing to Disclose
Jonathan G. Goldin, MBChB, PhD, Los Angeles, CA (Abstract Co-Author) Nothing to Disclose
PURPOSE

Systemic sclerosis (scleroderma, SSc) is a complex life-threatening autoimmune disease that affects multiple organ systems. Lung involvement is the leading cause of morbidity and mortality. The aim is to quantify the changes for monitoring the progression or improvement in interstitial lung disease (ILD) over time using voxel-by-voxel transitional scores.

METHOD AND MATERIALS

We report transitional scores using volumetric HRCT scans obtained from participants in SLSII who received either cyclophosphamide (CYC) (n=47) or mycophenolate mofetil (MMF)(n=50). The steps in this process include (1) lobar segmentation and classification of ILD patterns of quantitative lung fibrosis (QLF), quantitative ground glass (QGG), quantitative honeycomb (QHC), and quantitative normal lung (QNL); (2) registration of lobes between two paired scans; (3) mapping each voxel (<27mm3) using a nearest neighbor algorithm; (4) summarizing the transitional patterns into a ratio, where the ratio expresses the counts of changes from one pattern to the other to the counts of patterns at baseline; (5) integrating the transitional net-improvement  into a matrix across all patterns. Mixed effect models were used to compare the differences.

RESULTS

Means of the differences in the transitional proportions in the most severe lobe were as follows: CYC group 16% from fibrotic reticulation to GG, 21% from reticulation to normal pattern, and 31% from GG to normal pattern; MMF group 12%, 17%, and 28%, respectively. Similar means were found in whole lung.  Mean transitional net improvement from GG or fibrotic pattern to normal patterns and from fibrotic pattern to GG were significant in the two arms (all p<0.001).

CONCLUSION

Using voxel-by-voxel transitional scores on paired HRCT scans 24 months apart, we found obvious changes in extent of ILD patterns, indicating significant transitions from ground glass opacity or fibrotic reticulation to normal patterns and regionally dependent changes between fibrotic patterns and ground glass opacity in patients with SSc-ILD treated with either CYC or MMF.  These findings demonstrate the utility of serial HRCT scans and quantitative technique in monitoring the response to treatment in SSc-ILD, and provide insights into the nature of the therapeutic effects

CLINICAL RELEVANCE/APPLICATION

Registration-based transitional texture-based CT scores are effective in characterizing structural changes to therapy at each neighboring voxel level.